Live symbol workspace

GSK market intelligence

Chart context, AI evidence, sentiment, related news, and verified outcome history are grouped into one asset dossier.

Current $51.30

Trend Flat

Sentiment Neutral

{# Only render the live technical grid when the AI analysis carries real, non-placeholder data. Sentinel payloads (data_status error/collecting, current_price 0) are handled by the Asset Intelligence Dossier below, which degrades to a calm branded empty state instead of "0%" widgets. #}

Detailed Market Analysis

Key Levels

Support

$48.73

Resistance

$53.87

Volume & Momentum

Volume

Weak

0.8x avg

Momentum

0%

Weak

Technical Context

Current price

$51.30

RSI context

50

Market Sentiment

50

Neutral

Stock Metrics

Daily Vol

0%

VIX Est

20

Weekly

0%

Asset Intelligence Dossier

Provider track record

Not enough scored provider calls yet for this asset.

Confidence trend

41%

No prior-week baseline yet

Avg confidence across 9 calls in the last 7 days

What sources say

Bullish 2 articles

GSK Agrees to Buy Nuvalent for $10.6 Billion

GSK in talks to buy cancer biotech Nuvalent for more than $9bn

Insider Trading

Refreshing insider trades from FinViz…

Technical Observations

Refreshing technical observations from FinViz...

GSK News Intelligence (2 articles)

AI-curated news influencing GSK price, sentiment, and trend

Explore All GSK News with AI Analysis

Economy

4 days, 4 hours ago

GSK Agrees to Buy Nuvalent for $10.6 Billion

GSK agreed to buy Nuvalent in a deal valued at $10.6 billion, adding a biotech firm that’s developing treatments for …

Impact on GSK: The acquisition is likely to boost GSK's stock price, with potential positive …

GSK has agreed to acquire Nuvalent for $10.6 billion, expanding its oncology portfolio with lung … High (80%)

View full analysis →

Bloomberg 80% confidence

Global Markets & Finance

4 days, 10 hours ago

GSK in talks to buy cancer biotech Nuvalent for more than $9bn

A deal will rank as one of UK drugmaker’s biggest as biotech M&A activity has enjoyed an upswing this year

Impact on GSK: The potential acquisition of Nuvalent by GSK for over $9 billion could …

GSK is in talks to acquire cancer biotech Nuvalent for over $9 billion, marking one … High (80%)

View full analysis →

Financial Times 80% confidence